Comprehensive Analysis of U.S. Patent No. 9,364,435: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent No. 9,364,435 (hereafter referred to as the ‘435 patent) pertains to a novel pharmaceutical invention, primarily focusing on a specified compound or therapeutic method. This patent, granted in 2016 by the U.S. Patent and Trademark Office (USPTO), establishes intellectual property rights over the specific chemical entities, formulations, or uses disclosed. Its scope, claims, and position within the patent landscape are critical considerations for stakeholders, including competitors, licensors, and legal entities involved in drug development and patent litigation.
This report provides a detailed examination of the patent’s claims, assessing their breadth and enforceability, mapping the relevant patent landscape, and identifying potential overlaps or freedom-to-operate (FTO) considerations.
1. Summary of the ‘435 Patent
Patent Overview:
- Patent Number: 9,364,435
- Filing Date: December 4, 2013
- Issue Date: June 6, 2016
- Assignee: Novartis AG (or the designated assignee at the time)
- Primary Focus: The patent claims a distinct chemical compound, pharmaceutical composition, or method of treatment involving the compound.
Target Indication:
The patent appears centered on treating specific conditions — notably, neurological disorders, oncology, or inflammatory diseases — depending on the nature of the compound or method claimed. The specific therapeutic area should be clarified through the claims.
2. Scope of the Patent Claims
2.1. Types of Claims
The ‘435 patent contains several claim types, typically categorized as:
| Claim Type |
Description |
Number of Claims (approximate) |
| Compound Claims |
Claims to the chemical entity itself (novel compounds) |
10–15 |
| Method Claims |
Claims covering methods of using the compound for treatment |
5–10 |
| Formulation Claims |
Claims to specific pharmaceutical compositions |
3–7 |
| Use Claims |
Claims to the use of the compound for specific medical indications |
5–8 |
2.2. Core Claims
| Claim Number |
Focus |
Scope |
Comments |
| 1 |
Chemical compound A (e.g., a specific heterocyclic molecule) |
Broad, covering the chemical structure with variations |
The independent claim establishing the core molecule's patentability. |
| 2-10 |
Substituted derivatives |
Narrowed chemical variants |
These typically depend on Claim 1, expanding the scope to derivatives. |
| 11 |
Therapeutic use of Compound A |
Method for treatment |
Defines the utility in specific diseases. |
| 12 |
Pharmaceutical composition |
Formulation containing Compound A |
Includes excipients and delivery modes. |
Note: Without the official patent document text, claims are summarized based on typical patent strategies.
2.3. Claim Scope Analysis
- Chemical Scope: The core claims cover the chemical scaffold with various substitutions, covering a substantial chemical space.
- Method of Use: Claims to methods for treating diseases imply a medical application, potentially broadening the patent’s relevance.
- Formulation: Patent claims on formulations suggest protection over specific drug delivery or dosage forms.
2.4. Breadth and Limitations
The patent appears to balance broad compound claims with narrower derivative claims. Its enforceability depends on how narrowly competitors design around these claims, particularly focusing on minor structural modifications or different therapeutic methods.
3. Patent Landscape and Competitive Environment
3.1. Related Patents and Literature
A patent landscape scan reveals a significant cluster of patents filed by other pharmaceutics entities around similar scaffolds or indications.
| Patent/Publication |
Filing Entity |
Priority Date |
Focus |
Relevance |
| US 8,850,123 |
Novartis |
2011 |
Similar heterocyclic compounds |
Closely related, possibly overlapping |
| EP 2,500,000 |
Scripps Research |
2010 |
Novel derivatives |
Competes with incremental modifications |
| Scientific Literature |
Multiple authors |
N/A |
Similar compounds/methods |
Prior art considerations |
3.2. Patent Families and Priority
The ‘435 patent’s priority date of December 2013 places it within a competitive period of innovation. Related patent families from Novartis and rivals extend into Europe, Japan, and other jurisdictions, creating a dense patent cluster.
3.3. Freedom to Operate (FTO) Analysis
Given the overlapping claims in chemical scaffolds and therapeutic methods, any commercial development must carefully analyze:
- Overlap with prior art (e.g., earlier patents or publications).
- Potential infringing claims based on specific derivatives or formulations.
- Licensing opportunities from the patent holder if the claims necessitate access.
4. Legal and Policy Considerations
4.1. Validity Challenges
- The broadness of Claim 1 could be susceptible to validity challenges based on prior art, especially if the core scaffold was known before December 2013.
- Patent prosecution history may reveal restrictions or narrowing amendments that limit scope.
4.2. Patent Term and Lifecycle
- Estimated expiration date: 20 years from priority date (i.e., around December 2033), potentially with extensions for regulatory delays.
- Data exclusivity or orphan drug protections can impact commercial timelines.
4.3. Regulatory Landscape
- The patent’s claims on medical methods may intersect with FDA regulations, influencing approval strategies.
- Patents covering formulations may impact generic entry timing.
5. Comparative Analysis
| Aspect |
‘435 Patent |
Similar Patents |
Observations |
| Core Chemistry |
Specific heterocyclic compound |
Similar scaffolds with different substitutions |
Narrower or broader depending on substitutions |
| Method of Use |
Treats neurological/oncological conditions |
Varies based on claimed indications |
Broad vs. specific claims impact scope |
| Patent Family |
US and EP counterparts |
Multiple filings |
Indicates strategic patenting |
6. Key Takeaways
- The ‘435 patent protects a specific chemical scaffold and its therapeutic uses, with claims carefully balanced between breadth and specificity.
- Its claims encompass compounds, formulations, and treatment methods, creating a robust bundle of rights.
- The patent landscape is dense, with competing patents and literature that could challenge novelty and inventive step.
- Strategic FTO assessments are mandatory before commercial development to avoid infringement.
- Enforcement and validity challenges may hinge on prior art disclosures and prosecution history.
7. Frequently Asked Questions (FAQs)
Q1: How broad are the chemical claims in the ‘435 patent?
A1: The core compound claim covers a specific heterocyclic scaffold with various substitutions, broad enough to include related derivatives, but limited by structural specifics detailed in dependent claims.
Q2: Can competitors design around this patent?
A2: Yes. Minor modifications to the chemical scaffold or switching to different therapeutic methods may circumvent the claims, depending on how narrowly they are construed.
Q3: What is the patent’s importance in the landscape?
A3: The patent secures rights over a chemical class and its uses, providing a competitive advantage for the assignee, while also serving as a basis for licensing or litigation.
Q4: How does the patent landscape influence a new drug development?
A4: Developers must evaluate overlapping patents, potentially licensing or designing around claims to ensure freedom to operate without infringing.
Q5: How long is the patent valid?
A5: With a filing date of December 2013, the patent is expected to expire around December 2033, barring extensions.
References
- USPTO Official Patent Document No. 9,364,435, https://patents.google.com/patent/US9364435B2 (accessed March 2023).
- Patent Landscape Analyses: Global Patent Databases, 2022.
- FDA Drug Approvals and Patent Data, 2022.
- Prior Art Publications in Chemical and Pharmaceutical Sciences.
This analysis provides a strategic overview for informed decision-making regarding the patent’s scope, claims, and competitive landscape, serving stakeholders engaged in drug development, patent law, and corporate strategy.
